A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006–2021) who failed on two or more tyrosine kinase inhibitors (TKIs; third-line [3L]+ cohort) or harbored the <i>B...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/16/4161 |
| _version_ | 1797585200295706624 |
|---|---|
| author | Franck-Emmanuel Nicolini Françoise Huguet Lynn Huynh Churong Xu Christophe Bouvier Aurore Yocolly Gabriel Etienne |
| author_facet | Franck-Emmanuel Nicolini Françoise Huguet Lynn Huynh Churong Xu Christophe Bouvier Aurore Yocolly Gabriel Etienne |
| author_sort | Franck-Emmanuel Nicolini |
| collection | DOAJ |
| description | This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006–2021) who failed on two or more tyrosine kinase inhibitors (TKIs; third-line [3L]+ cohort) or harbored the <i>BCR::ABL1</i> T315I mutation (T315I cohort). In the 3L+ cohort (N = 157; median age at diagnosis, 56 years), TKIs received in 3L (median duration: 17 months) were dasatinib (32%), nilotinib (19%), imatinib (18%), ponatinib (17%), and bosutinib (14%). Of the 145 patients with documented responses in 3L, 42% experienced major molecular response (MMR) at 12 months. Median event-free survival [95% confidence interval] was 53.6 [44.0, 67.5] months, and median progression-free survival and overall survival (OS) were not reached. Achieving MMR in 3L was associated with a decreased mortality risk. In the T315I cohort (N = 17; 52 years), 41% of patients received five or more lines of therapy. Following identification of the T315I mutation, ponatinib was the most common TKI used (59%); the median [interquartile range] OS was 5 [3–10] years. The most common adverse events were infections (3L+ cohort) and thrombocytopenia (T315I cohort) (both 18%). Well-tolerated therapies that achieve durable responses are needed in 3L or earlier to improve CP-CML prognosis. |
| first_indexed | 2024-03-11T00:03:39Z |
| format | Article |
| id | doaj.art-b3aa639722a24f55a46bfec5fc336434 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T00:03:39Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b3aa639722a24f55a46bfec5fc3364342023-11-19T00:34:11ZengMDPI AGCancers2072-66942023-08-011516416110.3390/cancers15164161A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I MutationFranck-Emmanuel Nicolini0Françoise Huguet1Lynn Huynh2Churong Xu3Christophe Bouvier4Aurore Yocolly5Gabriel Etienne6Centre Léon Bérard, 69373 Lyon, FranceFi-LMC Group, 69437 Lyon, FranceAnalysis Group, Inc., Boston, MA 02199, USAAnalysis Group, Inc., Los Angeles, CA 90071, USACentre Léon Bérard, 69373 Lyon, FranceNovartis Services, Inc., East Hanover, NJ 07936, USAFi-LMC Group, 69437 Lyon, FranceThis retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006–2021) who failed on two or more tyrosine kinase inhibitors (TKIs; third-line [3L]+ cohort) or harbored the <i>BCR::ABL1</i> T315I mutation (T315I cohort). In the 3L+ cohort (N = 157; median age at diagnosis, 56 years), TKIs received in 3L (median duration: 17 months) were dasatinib (32%), nilotinib (19%), imatinib (18%), ponatinib (17%), and bosutinib (14%). Of the 145 patients with documented responses in 3L, 42% experienced major molecular response (MMR) at 12 months. Median event-free survival [95% confidence interval] was 53.6 [44.0, 67.5] months, and median progression-free survival and overall survival (OS) were not reached. Achieving MMR in 3L was associated with a decreased mortality risk. In the T315I cohort (N = 17; 52 years), 41% of patients received five or more lines of therapy. Following identification of the T315I mutation, ponatinib was the most common TKI used (59%); the median [interquartile range] OS was 5 [3–10] years. The most common adverse events were infections (3L+ cohort) and thrombocytopenia (T315I cohort) (both 18%). Well-tolerated therapies that achieve durable responses are needed in 3L or earlier to improve CP-CML prognosis.https://www.mdpi.com/2072-6694/15/16/4161chronic-phase chronic myeloid leukemia (CML-CP)tyrosine kinase inhibitor (TKI)treatment patternsoverall survivalT315I mutation |
| spellingShingle | Franck-Emmanuel Nicolini Françoise Huguet Lynn Huynh Churong Xu Christophe Bouvier Aurore Yocolly Gabriel Etienne A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation Cancers chronic-phase chronic myeloid leukemia (CML-CP) tyrosine kinase inhibitor (TKI) treatment patterns overall survival T315I mutation |
| title | A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation |
| title_full | A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation |
| title_fullStr | A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation |
| title_full_unstemmed | A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation |
| title_short | A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation |
| title_sort | multicenter retrospective chart review study of treatment and disease patterns and clinical outcomes of patients with chronic phase chronic myeloid leukemia in third line treatment or with t315i mutation |
| topic | chronic-phase chronic myeloid leukemia (CML-CP) tyrosine kinase inhibitor (TKI) treatment patterns overall survival T315I mutation |
| url | https://www.mdpi.com/2072-6694/15/16/4161 |
| work_keys_str_mv | AT franckemmanuelnicolini amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT francoisehuguet amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT lynnhuynh amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT churongxu amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT christophebouvier amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT auroreyocolly amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT gabrieletienne amulticenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT franckemmanuelnicolini multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT francoisehuguet multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT lynnhuynh multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT churongxu multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT christophebouvier multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT auroreyocolly multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation AT gabrieletienne multicenterretrospectivechartreviewstudyoftreatmentanddiseasepatternsandclinicaloutcomesofpatientswithchronicphasechronicmyeloidleukemiainthirdlinetreatmentorwitht315imutation |